LPCN
Lipocine Inc
NASDAQ · Pharmaceuticals
$8.49
+0.77 (+9.97%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 21.89M | 22.16M | 17.20M |
| Net Income | 3.29M | 3.56M | 2.74M |
| EPS | — | — | — |
| Profit Margin | 15.1% | 16.1% | 15.9% |
| Rev Growth | -6.8% | +9.7% | +22.0% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 5.17M | 4.92M | 5.58M |
| Total Equity | 36.33M | 36.70M | 40.60M |
| D/E Ratio | 0.14 | 0.13 | 0.14 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 4.47M | 4.85M | 3.77M |
| Free Cash Flow | 2.95M | 3.49M | 2.02M |